The criteria are: 70 years or younger, with clinically negative nodes, and having no significant comorbidities [15]. Additionally, the Society of Surgical Oncology (SSO) does not recommend routine use of SLNB in patients who are 70 years or older and have cN0, HER2+ cancer, and being treated with hormone therapy [25]. SSO recommendations state that there is no increase in cancer mortality or local recurrence associated with not doing a SLNB based on multiple studies [25,26]. Here, ERBB2 is linked to cancer.